Skip directly to page options Skip directly to A-Z link
Volume 25, Number 3—March 2019
Dispatch

Drug-Resistant Tuberculosis, Lebanon, 2016 – 2017

Salam El Achkar, Christine Demanche, Marwan Osman, Rayane Rafei, Mohamad Bachar Ismail, Hiam Yaacoub, Claire Pinçon, Stéphanie Duthoy, Frédérique De Matos, Cyril Gaudin, Alberto Trovato, Daniela M. Cirillo, Monzer Hamze, and Philip SupplyComments to Author 
Author affiliations: Université de Lille, CNRS, INSERM, Centre Hospitalier Universitaire, Institut Pasteur de Lille, U1019–UMR 8204–Centre d’Infection et d’Immunité de Lille, Lille, France (S. El Achkar, C. Demanche, C. Pinçon, P. Supply); Université Libanaise, Tripoli, Lebanon (S. El Achkar, M. Osman, R. Rafei, M.B. Ismail, M. Hamze); Genoscreen, Lille (S. Duthoy, F. De Matos, C. Gaudin); IRCCS San Raffaele Scientific Institute, Milan, Italy (A. Trovato, D.M. Cirillo); Ministry of Public Health, Beirut, Lebanon (H. Yaacoub)

Main Article

Table 1

Details of 250 TB cases with available phenotypic drug susceptibility profiles, Lebanon, 2016–2017*

Characteristic No. (%) patients
Total, n = 250 New cases, n = 228 Previously treated or relapsed, n = 18 Missing data, n = 4
Sex
M 128 (51.2) 112 (49.1) 14 (77.8) 2 (50)
F
 122 (48.8)
 116 (50.9)
 4 (22.2)
 2 (50)
Country of origin
Lebanon 70 (28) 64 (28.1) 4 (22.2) 2 (50)
Syria 74 (29.6) 65 (28.5) 9 (50) 0
Ethiopia 57 (22.8) 54 (23.7) 1 (5.6) 2 (50)
Bangladesh 13 (5.2) 13 (5.7) 0 0
Palestine 7 (2.8) 7 (3.1) 0 0
Other
 29 (11.6)
 25 (11)
 4 (22.2)
 0
Age, y
 34 ± 14
 34 ± 14
 38 ± 13
 23 ± 5
Drug resistance
RIF 7 (2.8) 3 (1.3) 4 (22.2) 0
Mono 1 (0.4) 1 (0.4) 0
MDR 3 (1.2) 1† (0.4) 2‡ (11.1)
XDR 3§ (1.2) 1§ (0.4) 2§ (11.1)
INH 16 (6.4) 15 (6.6) 1 (5.6) 0
Mono 9 (3.6) 8 (3.5) 1 (5.6)
INH + SM 7 (2.8) 7 (3.1) 0
EMB only 1 (0.4) 1 (0.4) 0 0
SM only 23 (9.2) 21 (9.2) 2 (11.1) 0
Susceptible to all first-line drugs 203 (81.2) 188 (82.4) 11 (61.1) 4 (100)

*Age is expressed as mean ±SD; categorical variables are presented as absolute numbers and percentages. EMB, ethambutol; INH, isoniazid; MDR, multidrug resistant; mono, monoresistant; RIF, rifampin; SM, streptomycin; XDR, extensively drug resistant.
†Resistant to RIF and INH.
‡Resistant to RIF, INH, EMB, and SM.
§Resistant to RIF, INH, EMB, SM, amikacin and kanamycin, and levofloxacin (representing all tested drugs for MDR and XDR isolates).

Main Article

Page created: February 19, 2019
Page updated: February 19, 2019
Page reviewed: February 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external